THE IMPACT OF PROTON PUMP INHIBITORS ON LARYNGOPHARYNGEAL REFLUX DISEASE
Main Article Content
Keywords
Laryngopharyngeal reflux, gastroesophageal reflux, proton pump inhibitors, rabeprazole, reflux symptom index, reflux finding score.
Abstract
Laryngopharyngeal reflux (LPR) is an extraesophageal manifestation of gastroesophageal reflux characterized by throat symptoms (hoarseness, chronic cough, globus). Proton pump inhibitors (PPIs) are first-line therapy, but evidence for their efficacy in LPR is mixed.
Objective: We evaluated the clinical impact of a PPI regimen on LPR symptoms and findings in a prospective interventional study.
Methods: One hundred adult patients with confirmed LPR (Reflux Symptom Index (RSI) ≥13 and Reflux Finding Score (RFS) >7) were enrolled. All received Rabeprazole 20 mg twice daily for 6 weeks. RSI and RFS were recorded before and after therapy. Secondary analyses assessed the influence of lifestyle factors (smoking, alcohol, diet). Data were analyzed using paired t-tests for RSI (normally distributed) and Wilcoxon signed-rank tests for RFS (non-normally distributed). A p-value <0.05 was considered statistically significant.
Results: Treatment yielded marked improvements. Mean RSI fell from 21.28 to 9.38 and mean RFS from 10.2 to 3.2 (both p<0.001). All individual RSI and laryngoscopic findings improved (p<0.001). Smokers experienced significantly less RFS improvement than non-smokers (p<0.05); alcohol use and diet did not significantly alter outcomes.
Conclusion: 6 weeks of high-dose rabeprazole significantly alleviated LPR symptoms and laryngeal findings in this study. The data support PPIs as an effective component of LPR management, though residual symptoms in some patients – especially smokers – highlight the importance of lifestyle modification and adjunctive therapies.
Keywords:
References
2. Gatta L, Vaira D, Sorrenti G, et al. Meta-analysis: efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25(4):385–392.
3. Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of RCTs. Am J Gastroenterol. 2006;101(11):2646–2654.
4. Jin X, Zhou X, Fan Z, Qin Y, Zhan J. Meta-analysis of proton pump inhibitors in the treatment of pharyngeal reflux disease. Comput Math Methods Med. 2022;2022:9105814.
5. Waxman J, Yalamanchali S, Valle ES, et al. Effects of proton pump inhibitor therapy for laryngopharyngeal reflux on posttreatment symptoms and hypopharyngeal pH. Otolaryngol Head Neck Surg. 2014;150(6):1010–1017.
6. Guo H, Ma H, Wang J. PPI therapy for laryngopharyngeal reflux: a meta-analysis of RCTs. J Clin Gastroenterol. 2016;50:295–300.
7. Bhargava A, Faiz SM, Srivastava M, et al. Role of proton pump inhibitors in laryngopharyngeal reflux: evaluation in a North Indian population. Indian J Otolaryngol Head Neck Surg. 2018;70(1):1–7.
8. Lam PKY, Ng ML, Cheung TK, et al. Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial. Clin Gastroenterol Hepatol. 2010;8(9):770–776.
9. Pokharel A, Mayya JP, Upadhyay H. Comparison of PPI and triple therapy regimen for laryngopharyngeal reflux. J Nepal Health Res Counc. 2020;18(3):513–519.
10. Ji JY, Huh G, Ji E, et al. Impact of twice-daily versus once-daily PPI dosing on laryngopharyngeal reflux symptoms: a prospective RCT. J Neurogastroenterol Motil. 2024;30:459–467.
11. Smit C.F. et al., “Effect of cigarette smoking on gastropharyngeal and gastroesophageal reflux” (Ann Otol Rhinol Laryngol. 2001;110(2):190–193)
12. Min C. et al., “Dietary modification for laryngopharyngeal reflux: systematic review” (J Laryngol Otol. 2019;133(2):80–86)